Altis Labs raises $25M Series A

OrbiMed and Qiming Venture Partners USA co-led the round. Innovation Endeavors, Benchstrength, Fusion Fund and Lumira Ventures, through the Cancer Breakthrough Fund, also took part. No valuation was published with the announcement. The Toronto company will use the money to expand its models across more cancer types and scale commercial deployment with global biopharma partners. Its product, IPRO, generates survival predictions from routine radiology scans. The model was trained with cancer centers on a multimodal oncology database spanning over 500,000 patient years. One report says the approach flags cancer drug effects up to 26 months before standard trial results. Trials today lean on measures such as objective response rate and progression-free survival. For AI founders, the round points to where money is moving in drug development. AI has made more progress finding drug candidates than proving they work in patients, according to Axios Pro. Altis is betting on validated evidence rather than discovery. The lesson for builders: proprietary longitudinal data and Phase 3 validation are the assets that get specialist healthcare funds to write checks.